1 / 14

Dr James Pickett james.pickett@alzheimers.uk

Alzheimer’s Society, UK Our research programme and the returns from research. Dr James Pickett james.pickett@alzheimers.org.uk. The landscape for funding in the EU. Joint Programming on Neurodegeneration(JPND). The landscape for funding in the UK. Total spend = ~£64 million

charlotte-walton
Télécharger la présentation

Dr James Pickett james.pickett@alzheimers.uk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Alzheimer’s Society, UK Our research programme and the returns from research Dr James Pickett james.pickett@alzheimers.org.uk

  2. The landscape for funding in the EU Joint Programming on Neurodegeneration(JPND)

  3. The landscape for funding in the UK Total spend = ~£64 million Source: Alzheimer’s Research UK annual accounts for 2008-2009

  4. The landscape for funding research in Alzheimer’s Society 2011 – 2012 expenditure £62million 2011 – 2012 expenditure on research ~£2.5million • Fund research into cause, care, cure and prevention of dementia • Value of portfolio £6million • Project grants (24), Fellowships (8), PhD studentships (17) • 60% of projects are predominantly animal or cell based projects • 40% of projects are human studies (autopsy tissue or patients) • 25% of projects involve people with dementia • Involvement of carers and people with dementia

  5. Outputs of the research grants programme in the last 12 months Funder of 50 publications • liraglutide prevents AD-like neurodegeneration in pre-clinical models of Alzheimer’s disease. Journal of Neuroscience. • A review on Alzheimer’s Disease in the leading journal. The Lancet Completion of several high profile clinical trials • Donepezil and memantine in moderate to severe AD (DOMINO) New England Journal of medicine, Thursday 8 March. • Aromatherapy to treat agitation in dementia Impact beyond publication • New referral service for people who are Deaf with cognitive complaints • Antipsychotics –development of a best-practice guide with The Department of Health • Development online training resources for GPs on the management of dementia and behavioural symptoms.

  6. Impact of research 1989 - 2011 ‘…it takes an average of 17 years for only 14 percent of scientific discoveries to become standard treatment in the community…’ Trochim et al, NIH report

  7. Impact of research 1989 - 2011 £18,800,000

  8. Impact of research 1989 - 2011

  9. Knowledge generation Impact of research 1989 - 2011

  10. Impact of research 1989 - 2011 Knowledge generation £80,000 per publication

  11. Impact of research 1989 - 2011 Knowledge generation • Have had an impact in research into cause, care, cure and prevention of dementia: • Tau biology • Important contributions to the field. • Diagnosis • Advances in MRI, blood biomarkers and improving diagnosis by GPs • Management of behavioural symptoms • FITS trial, CALM-AD

  12. Impact of research 1989 - 2011 • Developing leaders in dementia research • 36 research fellowships • 20 PhD studentships • 70 per cent of Alzheimer’s Society research fellows have remained active in dementia research. • 60 per cent of our research fellows now hold tenured positions in universities and research institutes.

  13. Impact of research 1989 - 2011 • Tangible improvements for people with dementia and their carers • A standard neuroimaging approach • Detection of brain atrophy by MRI is now a recommended approach for diagnosing early changes in dementia and is increasingly beginning to be used in clinical settings. • ‘Magnetic resonance imaging (MRI) is the preferred modality to assist with early diagnosis and detect subcortical vascular changes.’ • National Clinical guideline on supporting people with dementia and their carers in health and social care • Access to cholinesterase inhibitors in the UK • Alzheimer’s Society commissioned research that looked at the views and experiences of patients and carers in using these drugs, and creating novel patient-defined outcome measures. This evidence was crucial in Alzheimer’s Society’s campaigning work against the decision of NICE. • Person centred care as an alternative to antipsychotic medication • The FITS (focused intervention in training and support demonstrated a 50% reduction in antipsychotic use in care homes. Alzheimer’s Society has now started a role out of this package across the UK.

  14. Summary • Research is what many donors and supporters of our organisation wish their money to be spent on. • Research offers hope to patients and carers. • Research raises awareness of dementia and the profile of our organisation. • Research can innovate services and provide an evidence base to campaigns. • Research always adds to knowledge, can train new leaders in the field and occasionally can provide the breakthroughs that we strive for. Thank you!

More Related